We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.67%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.63B
AUM Growth
+$404M
(+18%)
Cap. Flow
+$126M
Cap. Flow
% of AUM
4.79%
Top 10 Holdings %
Top 10 Hldgs %
47.42%
Holding
84
New
20
Increased
43
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$35.6M |
| 3 |
AGN
Allergan plc
AGN
|
+$33.5M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$26.6M |
| 5 |
Biogen
BIIB
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$76.2M |
| 2 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$58.1M |
| 3 |
Amgen
AMGN
|
+$36.4M |
| 4 |
AGN
Allergan Inc
AGN
|
+$34.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
76
DELISTED
CATALENT, INC.
CTLT
| $445K | 0.02% |
+14,293
| New | +$412K |
|
77
Coherus Oncology
CHRS
$227M
| $387K | 0.01% |
+12,656
| New | +$327K |
|
78
Inogen
INGN
$174M
| – | – |
-206,734
| Closed | -$6.49M |
|
79
uniQure
QURE
$2.93B
| – | – |
-94,101
| Closed | -$1.39M |
|
|
80
Regeneron Pharmaceuticals
REGN
$77.4B
| – | – |
-185,685
| Closed | -$76.2M |
|
|
CBAY
81
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-708,585
| Closed | -$6.96M |
|
|
NPSP
82
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| – | – |
-1,623,073
| Closed | -$58.1M |
|
|
RNA
83
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
| – | – |
-111,432
| Closed | -$2.09M |
|
|
AGN
84
DELISTED
Allergan Inc
AGN
| – | – |
-162,750
| Closed | -$34.6M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sectoral Asset Management held 84 positions worth $2.63B, up 18% from $2.23B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sectoral Asset Management deployed $126M of net new capital in Q1 2015, opening 20 new positions and adding to 43 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.
On the sell side, the largest reduction was Amgen, an estimated $36.4M trimmed.
- Sectoral Asset Management's largest Q1 2015 buy was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
- Sectoral Asset Management added most to Gilead Sciences in Q1 2015, an estimated $64.6M increase.
- Sectoral Asset Management's biggest Q1 2015 reduction was Amgen, cutting an estimated $36.4M.
- Sectoral Asset Management fully exited Regeneron Pharmaceuticals in Q1 2015, selling an estimated $76.2M.
- Sectoral Asset Management's ten largest holdings make up 47% of its $2.63B portfolio in Q1 2015.
- Sectoral Asset Management opened 20 new positions and closed 7 in Q1 2015.
- Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $2.63B.
Based on Sectoral Asset Management's 13F filing for Q1 2015, filed 14 May 2015.